Leap Therapeutics Announced That Enrollment Of 188 Patients Has Been Completed In The Randomized Controlled Part B Of DeFianCe Study Of DKN-01 In Combination With Standard Of Care Bevacizumab And Chemotherapy As A Second-line Treatment For Advanced Colorectal Cancer
Portfolio Pulse from Benzinga Newsdesk
Leap Therapeutics has completed enrollment of 188 patients in the Part B of the DeFianCe study, which tests DKN-01 in combination with Bevacizumab and chemotherapy for advanced colorectal cancer.
September 30, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leap Therapeutics has completed patient enrollment in a key study for DKN-01, potentially advancing its treatment for advanced colorectal cancer.
The completion of patient enrollment in the DeFianCe study is a significant milestone for Leap Therapeutics, as it progresses towards potential new treatment options for colorectal cancer. This development could positively impact LPTX's stock price in the short term due to increased investor optimism about the company's pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100